Full notification file
General informationNotification NumberB/IE/14/02Member State to which the notification was sentIrelandDate of acknowledgement from the Member State Competent Authority14/04/2014Title of the ProjectA Phase I study to assess the safety and immunogenicity of prime-boost immunisations with vaccine candidates AdCh3NSmut1 and MVA-NSmut in HIV-1 seropositive HCV-uninfected adults on antiretroviral therapy (ART)Proposed period of release:01/07/2014 to 31/12/2015Name of the Institute(s) or Company(ies)St. James’s Hospital, The GUIDE Department, St. James’s Hospital, Dublin 8;
3. Is the same GMO release planned elsewhere in the Community?NoHas the same GMO been notified elsewhere by the same notifier?NoGMO characterizationGMO is a:DNA VirusIdentity of the GMO:1) Modified Vaccinia virus Anakara NSmut (MVA-NSmut)
Family: Poxviridae, Subfamily: Chordapoxviridae, Genus: Orthopoxviruses, Species: Vaccinia, Strain: MVA (Modified Vaccinia virus Ankara)Information relating to the recipient or parental organisms from wich the GMO is derived| Common Name | Genus | Species | Subspecies | Strain | Pathovar | | MVA | orthopoxvirus | vaccinia virus | - | Ankara | - |
|
Final report
European Commission administrative informationConsent given by the Member State Competent Authority:Not known